Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa with concurrent chemoradiation vs durvalumab after chemoradiation in unresectable stage III NSCLC
jRCT2080224688Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of bintrafusp alfa in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Started May 2019; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224688.